Want to see TSE:DOSE full AI Analyst Report?
Top Page
Rapid Dose Therapeutics Corp
(DOSE)
Select Model
Select Model
Rating:39Underperform
Price Target:
C$0.09
▲(0.00% Upside)
Action:Downgraded
Date:08/04/26
The score is driven primarily by weak financial performance, including declining revenue, deeply negative profitability (negative gross profit and large losses), and a highly stressed balance sheet with negative equity. Technicals add modest additional pressure with a weak longer-term trend and soft momentum indicators. Valuation remains unattractive due to ongoing losses (negative P/E) and no dividend support.
Positive Factors
Oral thin‑film drug‑delivery platform
A proprietary oral thin‑film delivery platform provides a durable strategic asset: it addresses multiple therapeutic and consumer‑health use cases, supports licensing or contract‑manufacturing models, and can create structural differentiation versus traditional pills over the medium term.
Negative Factors
Small and declining revenue base
A small revenue base (~$2.6M TTM) that is declining materially constrains the firm's ability to fund R&D, scale manufacturing, or attract large partners. Persistent revenue contraction undermines the commercial proof‑points needed to convert the platform into sustainable, recurring revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Oral thin‑film drug‑delivery platform
A proprietary oral thin‑film delivery platform provides a durable strategic asset: it addresses multiple therapeutic and consumer‑health use cases, supports licensing or contract‑manufacturing models, and can create structural differentiation versus traditional pills over the medium term.
Read all positive factors
Rapid Dose Therapeutics Corp (DOSE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$13.64M
Dividend YieldN/A
Average Volume (3M)36.09K
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue Growth4.30%
EPS Growth38.28%
CountryCA
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding136,444,840
10 Day Avg. Volume35,351
30 Day Avg. Volume36,089
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rapid Dose Therapeutics Corp Business Overview & Revenue Model
Company Description
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagshi...
How the Company Makes Money
null...
Rapid Dose Therapeutics Corp Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
34
Negative
| Breakdown | May 2026 | May 2025 | May 2024 | Nov 2022 | Feb 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.77M | 2.09M | 1.02M | 718.30K | 755.20K |
| Gross Profit | -956.89K | 1.18M | 563.41K | 372.40K | 699.85K |
| EBITDA | -1.66M | -3.93M | -3.02M | -2.92M | -987.00K |
| Net Income | -3.39M | -5.40M | -4.31M | -3.81M | -1.80M |
Balance Sheet | |||||
| Total Assets | 3.28M | 1.63M | 1.89M | 2.25M | 3.83M |
| Cash, Cash Equivalents and Short-Term Investments | 11.55K | 20.72K | 161.06K | 27.59K | 70.26K |
| Total Debt | 5.32M | 2.61M | 2.45M | 1.61M | 2.06M |
| Total Liabilities | 10.46M | 6.84M | 5.04M | 4.92M | 5.41M |
| Stockholders Equity | -7.18M | -5.21M | -3.16M | -2.67M | -1.58M |
Cash Flow | |||||
| Free Cash Flow | -271.29K | -1.15M | -2.29M | -863.92K | -1.63M |
| Operating Cash Flow | -270.39K | -1.15M | -2.29M | -863.92K | -1.62M |
| Investing Cash Flow | -899.00 | -5.74K | 0.00 | 0.00 | -9.12K |
| Financing Cash Flow | 262.13K | 1.01M | 2.43M | 856.53K | 1.65M |
Rapid Dose Therapeutics Corp Technical Analysis
Negative
0.09
Price Trends
0.10
Negative
0.10
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
50.20
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.20 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.
Rapid Dose Therapeutics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$41.58M | -0.28 | -147.92% | ― | ― | 85.31% | |
47 Neutral | C$10.55M | 0.81 | 240.12% | ― | ― | ― | |
46 Neutral | C$13.45M | -2.95 | 80.07% | ― | ― | 28.70% | |
39 Underperform | C$13.64M | -4.41 | 54.18% | ― | 4.30% | 38.28% |
* Healthcare Sector Average
TSE:DOSE
Rapid Dose Therapeutics Corp
0.11
-0.08
-43.24%
TSE:BCT
BriaCell Therapeutics
4.74
-5.16
-52.12%
TSE:HEM
Hemostemix
0.07
-0.02
-22.22%
TSE:BLAB
Britannia Life Sciences Inc
0.07
>-0.01
-13.33%
TSE:TELI
Telescope Innovations Corp
0.42
0.07
20.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.